keyword
MENU ▼
Read by QxMD icon Read
search

Vortioxetine

keyword
https://www.readbyqxmd.com/read/29344340/assessment-and-management-of-sexual-dysfunction-in-the-context-of-depression
#1
REVIEW
Pratap R Chokka, Jeffrey R Hankey
Sexual dysfunction (SD) is pervasive and underreported, and its effects on quality of life are underestimated. Due in part to its bidirectional relationship with depression, SD can be difficult to diagnose; it is also a common side effect of many antidepressants, leading to treatment noncompliance. While physicians often count on patients to spontaneously report SD, treatment is optimized when the clinician instead performs a thorough assessment of sexual functioning before and during drug therapy using a standardized questionnaire such as the Arizona Sexual Experiences Scale (ASEX)...
January 2018: Therapeutic Advances in Psychopharmacology
https://www.readbyqxmd.com/read/29331703/the-effects-of-vortioxetine-on-cognitive-performance-in-working-patients-with-major-depressive-disorder-a-short-term-randomized-double-blind-exploratory-study
#2
Bernhard T Baune, Lasse B Sluth, Christina K Olsen
BACKGROUND: Major Depressive Disorder (MDD) is a complex disease characterized by emotional, physical and cognitive symptoms. We explored the efficacy of vortioxetine versus placebo on outcomes of cognition, functioning and mood symptoms in working patients with depression, using paroxetine as an active reference. METHODS: Gainfully employed patients (18-65 years, N = 152) with MDD were randomized 1:1:1 to 8 weeks' double-blind, parallel treatment either with vortioxetine (10mg/day) or paroxetine (20mg/day), or with placebo...
December 28, 2017: Journal of Affective Disorders
https://www.readbyqxmd.com/read/29327372/relative-short-term-efficacy-and-acceptability-of-agomelatine-versus-vortioxetine-in-adult-patients-suffering-from-major-depressive-disorder
#3
Sidney H Kennedy, Jean-Marie Grouin, Stéphanie Cadour, Véronique Robert, Françoise Picarel-Blanchot
Agomelatine and vortioxetine are antidepressants with different mechanisms of action compared to other pharmaceutical treatment options. The objective of this present analysis is to determine the relative efficacy and acceptability of agomelatine (25-50 mg) compared to vortioxetine (10-15-20 mg) in adult patients with major depressive disorder. We performed an adjusted indirect comparison using placebo as a common control. The main outcomes were efficacy (response to treatment by Montgomery-Åsberg depression rating scale/Hamilton Rating Scale for Depression) and acceptability (withdrawal rate for any reason or due to adverse events)...
January 12, 2018: Human Psychopharmacology
https://www.readbyqxmd.com/read/29277417/reprint-of-contrasting-effects-of-vortioxetine-and-paroxetine-on-pineal-gland-biochemistry-in-a-tryptophan-depletion-model-of-depression-in-female-rats
#4
M Franklin, N Hlavacova, Y Li, I Bermudez, A Csanova, C Sanchez, D Jezova
We studied the effects of the multi-modal antidepressant, vortioxetine and the SSRI, paroxetine on pineal melatonin and monoamine synthesis in a sub-chronic tryptophan (TRP) depletion model of depression based on a low TRP diet. Female Sprague-Dawley rats were randomised to groups a) control, b) low TRP diet, c) low TRP diet+paroxetine and d) low TRP diet+vortioxetine. Vortioxetine was administered via the diet (0.76mg/kg of food weight) and paroxetine via drinking water (10mg/kg/day) for 14days. Both drugs resulted in SERT occupancies >90%...
December 23, 2017: Progress in Neuro-psychopharmacology & Biological Psychiatry
https://www.readbyqxmd.com/read/29274875/the-multimodal-antidepressant-vortioxetine-may-facilitate-pyramidal-cell-firing-by-inhibition-of-5-ht3-receptor-expressing-interneurons-an-in-vitro-study-in-rat-hippocampus-slices
#5
Elena Dale, Morten Grunnet, Alan L Pehrson, Kristen Frederiksen, Peter H Larsen, Jacob Nielsen, Tine B Stensbøl, Bjarke Ebert, Haolan Yin, Dunguo Lu, Huiquing Liu, Thomas N Jensen, Charles R Yang, Connie Sanchez
The multimodal antidepressant vortioxetine is thought to mediate its pharmacological effects via 5-HT1A receptor agonism, 5-HT1B receptor partial agonism, 5-HT1D, 5-HT3, 5-HT7 receptor antagonism and 5-HT transporter inhibition. Here we studied vortioxetine's functional effects across species (canine, mouse, rat, guinea pig and human) in cellular assays with heterologous expression of 5-HT3A receptors (in Xenopus oocytes and HEK-293 cells) and in mouse neuroblastoma N1E-115 cells with endogenous expression of 5-HT3A receptors...
December 21, 2017: Brain Research
https://www.readbyqxmd.com/read/29238196/the-role-of-new-antidepressants-in-clinical-practice-in-canada-a-brief-review-of-vortioxetine-levomilnacipran-er-and-vilazodone
#6
REVIEW
Roger S McIntyre
Although many branded and generic antidepressants are approved for the treatment of major depressive disorder (MDD) in Canada, efficacy and tolerability differ among patients, and new treatment options are needed. Symptom types (eg, fatigue, energy/motivation, cognition, and functioning), medication type, treatment duration, and the need for maintenance therapy are factors that may influence treatment effectiveness. Three antidepressants, vortioxetine, levomilnacipran extended-release (ER), and vilazodone have recently become available in Canada...
2017: Neuropsychiatric Disease and Treatment
https://www.readbyqxmd.com/read/29235884/cost-per-successfully-treated-patient-for-vortioxetine-versus-duloxetine-in-adults-with-major-depressive-disorder-an-analysis-of-the-complete-symptoms-of-depression-and-functional-outcome
#7
Michael Cronquist Christensen, Vicki Munro
OBJECTIVE: To determine the cost-effectiveness of vortioxetine versus duloxetine in adults with moderate to severe major depressive disorder (MDD) in Norway using a definition of a successfully treated patient (STP) that incorporates improvement in both mood symptoms and functional capacity. METHODS: Using the population of patients who completed the 8-week CONNECT study, the cost-effectiveness of vortioxetine (n = 168) (10-20 mg/day) versus duloxetine (n = 176) (60 mg/day) was investigated for the treatment of adults in Norway with moderate to severe MDD and self-reported cognitive dysfunction over an 8-week treatment period...
December 13, 2017: Current Medical Research and Opinion
https://www.readbyqxmd.com/read/29197738/efficacy-and-safety-of-levomilnacipran-vilazodone-and-vortioxetine-compared-with-other-second-generation-antidepressants-for-major-depressive-disorder-in-adults-a-systematic-review-and-network-meta-analysis
#8
REVIEW
Gernot Wagner, Marie-Therese Schultes, Viktoria Titscher, Birgit Teufer, Irma Klerings, Gerald Gartlehner
BACKGROUND: Second-generation antidepressants dominate the medical management of major depressive disorder (MDD). Levomilnacipran, vilazodone and vortioxetine are the latest therapeutic options approved for the treatment of MDD. This systematic review aims to compare the benefits and harms of vilazodone, levomilnacipran, and vortioxetine with one another and other second-generation antidepressants. METHODS: We searched electronic databases up to September 2017 and reviewed reference lists and pharmaceutical dossiers to detect published and unpublished studies...
November 16, 2017: Journal of Affective Disorders
https://www.readbyqxmd.com/read/29189941/vortioxetine-clinical-pharmacokinetics-and-drug-interactions
#9
REVIEW
Grace Chen, Astrid-Maria Højer, Johan Areberg, George Nomikos
Vortioxetine is a novel antidepressant with multimodal activity currently approved for the treatment of major depressive disorder. Vortioxetine is orally administered once daily at 5- to 20-mg doses. The pharmacokinetics of vortioxetine are linear and dose proportional, with a mean terminal half-life of approximately 66 h and steady-state plasma concentrations generally achieved within 2 weeks of dosing. The mean absolute oral bioavailability of vortioxetine is 75%. No food effect on pharmacokinetics was observed...
November 30, 2017: Clinical Pharmacokinetics
https://www.readbyqxmd.com/read/29174531/can-we-increase-speed-and-efficacy-of-antidepressant-treatments-part-i-general-aspects-and-monoamine-based-strategies
#10
REVIEW
Francesc Artigas, Analia Bortolozzi, Pau Celada
Major depressive disorder (MDD) is a severe psychiatric syndrome with high prevalence and socioeconomic impact. Current antidepressant treatments are based on the blockade of serotonin (5-hydroxytryptamine, 5-HT) and/or noradrenaline transporters. These drugs show slow onset of clinical action and limited efficacy, partly due to the activation of physiological negative feed-back mechanisms operating through autoreceptors (5-HT1A, 5-HT1B, α2-adrenoceptors) and postsynaptic receptors (e.g., 5-HT3). As a result, clinically-relevant doses of reuptake inhibitors increase extracellular (active) 5-HT concentrations in the midbrain raphe nuclei but not in forebrain, as indicated by rodent microdialysis studies and by PET-scan studies in primate/human brain...
November 21, 2017: European Neuropsychopharmacology: the Journal of the European College of Neuropsychopharmacology
https://www.readbyqxmd.com/read/29166552/vortioxetine-versus-placebo-in-major-depressive-disorder-comorbid-with-social-anxiety-disorder
#11
Michael R Liebowitz, Jason Careri, Kyra Blatt, Ann Draine, Junko Morita, Melissa Moran, Rita Hanover
BACKGROUND: Major Depressive Disorder (MDD) and Social Anxiety Disorder (SAD) are highly comorbid, yet the combined condition has not been subject to any placebo-controlled treatment trials. This study reports a trial of vortioxetine, an antidepressant that has also shown benefit in Generalized Anxiety Disorder (GAD), in patients meeting DSM-5 criteria for both MDD and SAD. METHODS: The study was a 12-week double-blind, placebo-controlled comparison of vortioxetine 10-20 mg/day or placebo administered on a 1:1 ratio...
December 2017: Depression and Anxiety
https://www.readbyqxmd.com/read/29160598/a-randomized-8-week-double-blind-placebo-controlled-trial-of-vortioxetine-in-japanese-adults-with-major-depressive-disorder-followed-by-a-52-week-open-label-extension-trial
#12
Takeshi Inoue, Akira Nishimura, Kiyofumi Sasai, Tadayuki Kitagawa
AIM: Safety and efficacy of vortioxetine (5-20 mg/day) in Japanese patients with major depressive disorder were evaluated in two phase 3 studies consisting of a short-term, 8-week, placebo-controlled, double-blind study followed by a long-term, 52-week, open-label extension study. METHODS: The primary endpoint of the short-term study was change from baseline in Montgomery-Åsberg Depression Rating Scale (MADRS) total score at week 8. The primary objective of the extension study was vortioxetine's long-term safety; efficacy endpoints included change in MADRS total score, clinical global impression scale-severity (CGI-S) score from the long-term study baseline, and clinical global impression scale-improvement (CGI-I) score over 52 weeks...
November 21, 2017: Psychiatry and Clinical Neurosciences
https://www.readbyqxmd.com/read/29154157/efficacy-of-antidepressants-on-measures-of-workplace-functioning-in-major-depressive-disorder-a-systematic-review
#13
REVIEW
Yena Lee, Joshua D Rosenblat, JungGoo Lee, Nicole E Carmona, Mehala Subramaniapillai, Margarita Shekotikhina, Rodrigo B Mansur, Elisa Brietzke, Jae-Hon Lee, Roger C Ho, Samantha J Yim, Roger S McIntyre
INTRODUCTION: Work-related disability and productivity loss in Major Depressive Disorder (MDD) are critical determinants of patient quality of life and contribute significantly to the human and economic costs of MDD. Notwithstanding the return to work and pre-morbid levels of functioning as a critical therapeutic objective among individuals with MDD, it is unclear whether antidepressant treatment significantly and reliably improves measures of workplace functioning. Herein, we investigate to what extent antidepressant treatment improves workplace functioning among adults with MDD...
November 7, 2017: Journal of Affective Disorders
https://www.readbyqxmd.com/read/29149828/vortioxetine-treatment-for-anxiety-disorder-a-meta-analysis-study
#14
Anne Yee, Chong Guan Ng, Loh Huai Seng
BACKGROUND: Vortioxetine is a multimodal antidepressant that has been developed for the treatment of major depressive and anxiety disorders. The aim of this review is to quantitatively synthesize all data of the efficacy, safety and tolerability of Vortioxetine in treating anxiety disorder. METHOD: Terms of "Vortioxetine" OR "LuAA21004" AND "anxiety" OR "fear" OR "panic" OR "phobia" were searched. A total of two phase II and five phase III clinical trials were found...
November 17, 2017: Current Drug Targets
https://www.readbyqxmd.com/read/29127931/efficacy-and-tolerability-of-different-doses-of-three-new-antidepressants-for-treating-major-depressive-disorder-a-prisma-compliant-meta-analysis
#15
Hairong He, Wei Wang, Jun Lyu, Jie Zheng, Liyang Guo, Xiaofang An, Yajuan Fan, Xiancang Ma
In last decade, the US FDA has approved three new antidepressants: vortioxetine, levomilnacipran, and vilazodone. Many studies have researched the effects of these antidepressants on major depressive disorder (MDD), but they have not determined the optimum dosage. This meta-analysis investigated the efficacies of these three drugs at different dosages in the treatment of MDD. The PubMed, Embase, Cochrane Library, psycINFO, and ClinicalTrials.gov databases were searched to identify relevant literature. The primary outcomes were efficacy [quantified as the change from baseline in total score on the Montgomery-Asberg Depression Rating Scale (MADRS)] and tolerability (discontinuations due to adverse events)...
January 2018: Journal of Psychiatric Research
https://www.readbyqxmd.com/read/29123483/impact-of-vortioxetine-on-synaptic-integration-in-prefrontal-subcortical-circuits-comparisons-with-escitalopram
#16
Shreaya Chakroborty, Thomas R Geisbush, Elena Dale, Alan L Pehrson, Connie Sánchez, Anthony R West
Prefrontal-subcortical circuits support executive functions which often become dysfunctional in psychiatric disorders. Vortioxetine is a multimodal antidepressant that is currently used in the clinic to treat major depressive disorder. Mechanisms of action of vortioxetine include serotonin (5-HT) transporter blockade, 5-HT1A receptor agonism, 5-HT1B receptor partial agonism, and 5-HT1D, 5-HT3, and 5-HT7 receptor antagonism. Vortioxetine facilitates 5-HT transmission in the medial prefrontal cortex (mPFC), however, the impact of this compound on related prefrontal-subcortical circuits is less clear...
2017: Frontiers in Pharmacology
https://www.readbyqxmd.com/read/29113521/efficacy-and-safety-of-vortioxetine-for-the-treatment-of-major-depressive-disorder-a-randomised-double-blind-placebo-controlled-study
#17
Jing Wang, Xi-Fang Liu, Chong Feng, Quan Bao, Hong-Ran Fu
OBJECTIVE: This study aimed to evaluate the efficacy and adverse events of vortioxetine for Chinese patients with major depressive disorder (MDD) over 10 weeks. METHODS: A total of 120 patients with MDD were randomly assigned to two groups that received vortioxetine 20 mg or placebo for 10 weeks. The outcomes were the change from baseline in the Montgomery-Åsberg Depression Rating Scale (MADRS), Hamilton Anxiety Rating Scale (HAM-A), Clinical Global Impressions-Improvement (CGI-I) scale, Sheehan Disability Scale (SDS) at Week 10, and the presence of adverse events...
November 7, 2017: International Journal of Psychiatry in Clinical Practice
https://www.readbyqxmd.com/read/29104073/acute-effects-of-vortioxetine-and-duloxetine-on-resting-state-functional-connectivity-in-the-awake-rat
#18
Pablo D Pérez, Zhiwei Ma, Christina Hamilton, Connie Sánchez, Arne Mørk, Alan L Pehrson, Christoffer Bundgaard, Nanyin Zhang
The antidepressant vortioxetine exerts its effects via modulation of several serotonin (5-HT) receptors and inhibition of the 5-HT transporter (SERT). Additionally, vortioxetine has beneficial effects on aspects of cognitive dysfunction in depressed patients. However, a global examination of the drug effect on brain network connectivity is still missing. Here we compared the effects of vortioxetine and a serotonin norepinephrine reuptake inhibitor, duloxetine, on resting-state functional connectivity (RSFC) across the whole brain in awake rats using a combination of pharmacological and awake animal resting-state functional magnetic resonance imaging (rsfMRI) techniques...
November 2, 2017: Neuropharmacology
https://www.readbyqxmd.com/read/29102760/partial-inhibition-of-catecholamine-activity-and-enhanced-responsiveness-to-nmda-after-sustained-administration-of-vortioxetine
#19
Mohammad Ebrahimzadeh, Mostafa El Mansari, Pierre Blier
Vortioxetine is a multimodal drug that blocks serotonin (5-HT) reuptake and directly modulates 5-HT receptors. The effects of subacute and long-term administration of vortioxetine on various aspects of catecholamine and glutamate systems were investigated using single-unit extracellular recordings and microiontophoresis in the rat brain. The firing rate of dopamine (DA) neurons was significantly decreased (26%) after 14, but not 4 days of vortioxetine administration (vortioxetine-containing chow, 1.8 g/kg vortioxetine)...
January 2018: Neuropharmacology
https://www.readbyqxmd.com/read/29081307/efficacy-of-vortioxetine-in-working-patients-with-generalized-anxiety-disorder
#20
Michael Cronquist Christensen, Henrik Loft, Ioana Florea, Roger S McIntyre
BACKGROUND: Vortioxetine is an approved antidepressant that has also demonstrated positive effects on anxiety symptoms in subjects with generalized anxiety disorder (GAD). This post-hoc analysis evaluates the efficacy of vortioxetine in GAD subjects who are working and/or pursuing an education. METHODS: In study NCT00744627, 301 GAD subjects were randomized to vortioxetine 5 mg or placebo for 8 weeks. Efficacy measures included the Hamilton Anxiety Rating Scale (HAM-A) total score, response/remission, global functioning (Sheehan Disability Scale [SDS]), and quality of life (Short Form-36 Health Survey)...
October 30, 2017: CNS Spectrums
keyword
keyword
22035
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"